There are currently 2925 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and Texas Children's Hospital. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Preterm Functional Early Enteral Development (FEED) Trial on Respiratory Support
Recruiting
The purpose of this study is to demonstrate that allowing infants that require high flow nasal cannula (HFNC)/Continuous positive airway pressure (CPAP) to orally feed if demonstrating oral cues will achieve full oral feeds faster.
Gender:
All
Ages:
32 weeks and above
Trial Updated:
05/19/2022
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Premature Birth
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
Recruiting
The purpose of this study is to characterize the cortical connectivity changes in the brain of spastic diplegic children after Selective Dorsal Rhizotomy.
Gender:
All
Ages:
Between 3 years and 18 years
Trial Updated:
05/17/2022
Locations: UTHealth & Children's Memorial Hermann Hospital, Houston, Texas
Conditions: Spastic Diplegia
Diffusion Tensor and Functional Connectivity Imaging in Pediatric Epilepsy: Imaging/Histology Correlation
Recruiting
To determine the utility of diffusion tensor magnetic resonance imaging in the preoperative workup of children with intractable epilepsy referred for surgery.
Gender:
All
Ages:
Between 0 days and 18 years
Trial Updated:
05/17/2022
Locations: UTHealth & Children's Memorial Hermann Hospital, Houston, Texas
Conditions: Intractable Epilepsy
Computer Aided Polyp Detection (C3PO) Trial
Recruiting
Computer aided detection (CADe) algorithms have been developed to overcome human errors and assist endoscopists in detecting more polyps during colonoscopy. The aim of this study was to investigate the accuracy of the novel Pentax Discovery CADe system (Discovery-AI) against pre-recorded videos of colon polyps of various size, shape and pathology while using videos of normal colon segments as controls from two different institutes.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2022
Locations: Memorial Hermann Hospital, Houston, Texas
Conditions: Colonic Polyp
CHoice of OptImal transCatheter trEatment for Mitral Insufficiency Registry
Recruiting
This multinational, investigator-initiated, retrospective study aims to investigate outcomes of patients, who underwent transcatheter mitral valve implantation (TMVI), in comparison to those screened for TMVI but deemed ineligible, who subsequently underwent interventional mitral valve edge-to-edge repair, mitral valve surgery or medical/conservative therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2022
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Mitral Regurgitation
A Prospective Study To Identify Predictive Biological Markers In Blood And Cyst Fluid Aspirates From Patients With Pancreatic Cyst Lesions
Recruiting
The purpose To determine the diagnostic potential of various biological markers in blood and cyst fluid aspirates from patients with Pancreatic Cystic Lesions (PCLs). Research design This is a 10-year prospective cohort and pancreatic cyst fluid repository study enrolling all patients diagnosed with pancreatic cyst and undergoing the cyst aspiration. Procedures to be used Blood Sample Cyst Fluid Sample Data Collection: Medical Record Number Demographics (age, sex, gender, race) Contact infor... Read More
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/16/2022
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Pancreatic Cystic Lesions
YL-13027 in Patients With Advanced Solid Tumors
Recruiting
Part 1 (Phase Ia): This is a dose escalation, 3 + 3 design study, to evaluate the safety and tolerability, and to determine the RP2D of YL-13027 when administered b.i.d. in patients with advanced solid tumors. Up to 4 cohorts of 3-6 patients each will be treated in part 1 of the study. One cycle is 28 days. Part 2: This is a dose expansion phase to further evaluate the safety, tolerability and preliminary anti-tumor activity of YL-13027 at the RP2D.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/16/2022
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumor
EEG Brain-Machine Interface Control of an Upper-Limb Robotic Exoskeleton for Robot-Assisted Rehabilitation After Stroke
Recruiting
The goal of this study is to develop a clinically feasible, low-cost, nonsurgical neurorobotic system for restoring function to motor-impaired stroke survivors that can be used at the clinic or at home. Moreover, another goal is to understand how physical rehabilitation assisted by robotic device combined with electroencephalograph (EEG) can benefit adults who have had stroke to improve functions of their weaker arm. The proposed smart co-robot training system (NeuroExo) is based on a physical... Read More
Gender:
All
Ages:
Between 20 years and 65 years
Trial Updated:
05/10/2022
Locations: The Institute for Rehabilitation and Research (TIRR) at Memorial Hermann, Houston, Texas +2 locations
Conditions: Stroke, Hemiparesis
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
Recruiting
This is a two-part study designed to evaluate the effect of Estetrol (E4) 15 or 20 mg, or placebo on the severity and frequency of vasomotor symptoms (VMS) (Efficacy Study Part) and the safety of E4 20 mg (Endometrial and General Safety Study Part)
Gender:
Female
Ages:
Between 40 years and 65 years
Trial Updated:
05/09/2022
Locations: Biopharma Informatic, Inc. Research Center, Houston, Texas
Conditions: Vasomotor Symptoms, Menopausal Symptoms
Ruxolitinib for Premalignant Breast Disease
Recruiting
This study is evaluating how ruxolitinib affects premalignant breast cells. One half of the study participants will receive ruxolitinib for approximately 15 days, and the other half will receive a placebo (sugar pill) for approximately 15 days. Once study participants have completed their ruxolitinib or placebo, participants will undergo surgery to remove the premalignant breast tissue.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/09/2022
Locations: Baylor College of Medicine, Houston, Texas +1 locations
Conditions: Ductal Carcinoma In Situ, Atypical Lobular Hyperplasia, Atypical Ductal Hyperplasia, Lobular Carcinoma In Situ
Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis
Recruiting
This study evaluates either KRT-232 or TL-895 in treatment naïve patients with myelofibrosis (MF) The study will be conducted in 2 stages. Stage 1 will evaluate safety, tolerability, and efficacy of either KRT-232 (Arm 1) or TL-895 (Arm 2) in treatment naïve patients. Stage 2 will expand enrollment in Arm 1 and/or Arm 2 if expansion criteria is met.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/05/2022
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV-MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib
Recruiting
This is a phase 1b/2 study of KRT-232 combined with ruxolitinib in subjects with MF who have a suboptimal response after at least 18 weeks of treatment with ruxolitinib. The primary objective of the study is to determine a recommended phase 2 dose (RP2D) of KRT 232 in combination with ruxolitinib.
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
05/05/2022
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Myelofibrosis